Volixibat potassium is a small molecule commercialized by Mirum Pharmaceuticals, with a leading Phase II program in Pruritus. According to Globaldata, it is involved in 11 clinical trials, of which 7 were completed, 2 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Volixibat potassium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Volixibat potassium is expected to reach an annual total of $29 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Volixibat potassium Overview

Volixibat potassium (SHP-626, LUM-002) is under development for primary sclerosing cholangitis and its associated pruritus and primary biliary cholangitis. It is administered through the oral route as a capsule. The drug candidate selectively targets apical sodium-dependent bile acid transporter (ASBT). The human apical sodium-dependent bile acid transporter (SLC10A2) belongs to the solute carrier family (SLC) of transporters and is an important carrier protein expressed in the small intestine.

It was also under development for the treatment of nonalcoholic steatohepatitis (NASH) by Shire, adult cholestasis (intrahepatic cholestasis of pregnancy), and Type 2 diabetes.

Mirum Pharmaceuticals Overview

Mirum Pharmaceuticals is biopharmaceutical company that develops a pipeline of novel therapies for debilitating liver diseases. The company’s pipeline products include Maralixabat, minimally absorbed, orally administered investigational drug and Volixibat, a minimally absorbed agent designed to selectively inhibit ASBT. It develops products to treat rare cholestatic liver diseases that include progressive familial intrahepatic cholestasis (PFIC), alagille syndrome (ALGS), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP). Mirum Pharmaceuticals is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$19.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$65.4 million in FY2021, compared to an operating loss of US$104.3 million in FY2020. The net loss of the company was US$84 million in FY2021, compared to a net loss of US$103.3 million in FY2020. The company reported revenues of US$18.8 million for the third quarter ended September 2022, an increase of 7.4% over the previous quarter.

For a complete picture of Volixibat potassium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.